Clinical trials, such as SURMOUNT-1 and SURPASS-2, follow escalation intervals of 4 weeks, reaching 10 mg or 15 mg in most participants
doi: 10.1371/journal.pone.0011624
Journal of Cellular and Molecular Medicine, 15, 1703-1712
Gondo et al, Growth Hormone-Releasing Peptide-2 Stimulates GH Secretion in GH-Deficient Patients with Mutated GH-Releasing Hormone Receptor, The Journal of Clinical Endocrinology & Metabolism, Volume 86, Issue 7, 1 July 2001, Pages 32793283, Adrian S, Scherzinger A, Sanyal A, Lake JE, Falutz J, Dub MP, Stanley T, Grinspoon S, Mamputu JC, Marsolais C, Brown TT, Erlandson KM
Despite tirzepatide being commercially available, OSA patients may seek out compounded tirzepatide due to concerns about out-of-pocket costs or due to its easy accessibility via online pharmacies, without being aware of compounded tirzepatides safety risks
Further time is necessary to reach out about the consequences of OAGB in the future